NMRA news

Latest 3 stories · newest Jul 27, 2026

NMRA

Neumora reports favorable NMRA-215 toxicology results

Neumora Therapeutics reported positive preclinical toxicology data for its NLRP3 inhibitor NMRA-215. The results support the advancement of the drug candidate to the clinic. The company plans to file its IND in late 2026.

Regulatory Jul 27, 2026 sentiment 0.00 SEC filing ↗

NMRA

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

News Jun 16, 2026 sentiment 0.00 Source: benzinga.com ↗

NMRA

Neumora discontinues navacaprant after Phase 3 failures in depression

Neumora's Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to meet primary endpoints for major depressive disorder, prompting the company to halt development. The company is implementing a 35% workforce reduction and refocusing on three pipeline programs with cash runway through Q3 2027.

Regulatory Jun 15, 2026 sentiment -0.65 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same NMRA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/NMRA/newsSTART FREE